Microsens' vCJD (variant Creutzfeldt-Jakob disease) trials may start in 12 months:
This article was originally published in Clinica
Executive Summary
Microsens Biotechnologies has told Clinica that it expects to begin human trials of its human variant Creutzfeldt-Jakob disease (vCJD) blood test within the next 12 months. The test uses a ligand-based technology called Seprion to identify abnormal prion proteins in the blood (see Clinica No 1125, p 21). The firm's comment follows this month's EU approval of Idexx Laboratories' BSE test, HerdChek, which uses Microsens' Seprion technology. Microsens CEO, Christopher Stanley, said that Idexx' EU approval represented "another stake in the ground towards providing a vCJD blood test." The London, UK-based company said it would need 20-30 positive vCJD blood samples to begin the trials.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.